scholarly journals iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma

2016 ◽  
Vol 10 (3) ◽  
pp. 210-219 ◽  
Author(s):  
Limin Zhang ◽  
Haowen Jiang ◽  
Gang Xu ◽  
Nan Chu ◽  
Ningxing Xu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Clear Cell ◽  
Diagnostic Markers ◽  
Cell Renal Cell Carcinoma ◽  
Quantitative Proteomic Analysis ◽  
Early Diagnostic

scholarly journals Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma

Oncotarget ◽  
2014 ◽  
Vol 5 (2) ◽  
pp. 506-518 ◽  
Author(s):  
Nicole M.A. White ◽  
Olena Masui ◽  
Leroi V. DeSouza ◽  
Olga Krakovska ◽  
Shereen Metias ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Diagnostic Markers ◽  
Quantitative Proteomic Analysis

Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE

2012 ◽  
Vol 8 (4) ◽  
pp. 1040 ◽  
Author(s):  
Francesca Raimondo ◽  
Claudia Salemi ◽  
Clizia Chinello ◽  
Daniela Fumagalli ◽  
Lavinia Morosi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Clear Cell ◽  
Differentially Expressed ◽  
Cell Renal Cell Carcinoma ◽  
Differentially Expressed Protein

Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades

2019 ◽  
Vol 191 ◽  
pp. 38-47 ◽  
Author(s):  
Martina Stella ◽  
Clizia Chinello ◽  
Anna Cazzaniga ◽  
Andrew Smith ◽  
Manuel Galli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Molecular Profiles

Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 585-585 ◽  
Author(s):  
Patrick Glen Pilie ◽  
Lijun Zhou ◽  
Christine B Peterson ◽  
Yang Peng ◽  
Guang Peng ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
In Silico ◽  
Renal Cell ◽  
Clear Cell ◽  
Early Stage ◽  
Gene Signature ◽  
Cell Renal Cell Carcinoma ◽  
Tumor Stages

585 Background: Clear cell renal cell carcinoma (ccRCC) displays genomic instability across all tumor stages, indicative of increased replicative stress and defects in DNA damage response (DDR) pathways including homologous repair (HR); however ccRCC does not display mutations in canonical DDR genes and advanced ccRCC is not traditionally sensitive to DNA damaging agents. We hypothesized that biallelic VHL loss is sufficient to cause HR deficiency (HRD) and that early stage ccRCC is more likely to display HRD than late stage disease. Methods: We performed whole-exome (WES) sequencing of 15 small ccRCC tumors to assess for mutational burden, mutational signature, and cancer-related driver gene mutations. We performed in silico genomic, transcriptomic, and proteomic analysis of tumors in KIRC TCGA to assess for HRD. Finally, we assessed HR efficiency as a product of biallelic VHL loss in engineered cell line models. Results: 15/15 early stage ccRCC had VHL mutations, approximately 100 additional mutations per tumor, but no common mutations found in KIRC TCGA. In silico analysis showed 67% of KIRC TCGA displayed HRD gene signature, and was significantly higher in stage I disease (p = 2.21e-08). Patients with VHL-mutated tumors are more commonly HRD than HR intact (HRI) (p = 0.03), with frameshift/nonsense variants in VHL more likely to result in HRD than missense variants (p = 0.02). Multivariate analysis showed HRD predicted for better overall survival compared to HRI (p < 0.0001). Proteomic analysis of KIRC TCGA revealed HRI samples had significantly higher protein expression of Rad51 and RAPTOR when compared to HRD samples. Lastly, etoposide-treated MEF Vhl-/- cell lines displayed reduced HR efficiency when compared to Vhl intact controls. Conclusions: Biallelic loss of VHL is sufficient to cause HRD. HRD gene signature predicts for significantly better OS in ccRCC patients, and early stage ccRCC is more likely to be HRD. mTOR/PI3K signaling pathway proteins are differentially expressed in HRI patient samples from TCGA compared to HRD, suggesting a possible role for these oncogenes driving a HRI phenotype. Treatment strategies combining PARP inhibitors with PI3K/mTOR inhibitors should be tested in advanced VHL-mutated ccRCC.

Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma

2016 ◽  
Vol 34 (1) ◽  
pp. 5.e11-5.e25 ◽  
Author(s):  
Vanessa Sandim ◽  
Denise de Abreu Pereira ◽  
Dário Eluan Kalume ◽  
Ana Lucia Oliveira-Carvalho ◽  
Antonio Augusto Ornellas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Clear Cell ◽  
Secreted Proteins ◽  
Cell Renal Cell Carcinoma

scholarly journals Early Diagnostic and Prognostic Value of BIRC5 in Clear Cell Renal Cell Carcinoma Based on TCGA Data

2020 ◽  
Author(s):  
Jingyuan Wang ◽  
Min Chen ◽  
Chengxue Dang ◽  
Hao Zhang ◽  
Xin Wang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Early Diagnosis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Clinicopathological Parameters ◽  
Normal Kidney ◽  
Cell Renal Cell Carcinoma ◽  
Important Indicator ◽  
Early Diagnostic

Abstract Purpose: Clear cell renal cell carcinoma (ccRCC) is a highly lethal cancer that would benefit from non-invasive innovative markers providing early diagnostic and prognostic detection. Increased BIRC5 (baculoviral inhibitor of apoptosis repeat containing 5) expression is associated with negative outcomes or survival in various cancers. Our study aims to investigate the role of BIRC5 of early diagnosis and prognosis in ccRCC by studying the expression of BIRC5 and the correlation between BIRC5 expression and clinicopathological parameters, prognosis in ccRCC. Methods: The BIRC5 expression in ccRCC tissues and normal kidney tissues was measured using the Cancer Genome Atlas (TCGA) database and The Human Protein Atlas database. The correlation between BIRC5 expression and clinicopathological parameters, prognosis in ccRCC was analyzed using UALCAN, Kaplan Meier plotter, GEPIA and SurvExpress. Results: BIRC5 expression is significantly higher in ccRCC than in normal kidney tissues, and is correlated with the clinical stage and pathological grade of ccRCC(P<0.05). The result of analyzing the relationship between BIRC5 expression and outcomes in ccRCC indicates that high BIRC5 expression is an independent prognostic factor affecting overall survival and disease-free survival of ccRCC (P<0.05). Compared with normal kidney tissues, the immunohistochemical test shows that BIRC5 is significantly upregulated in ccRCC tissues. Conclusions: The high expression of BIRC5 is an important indicator of the prognosis of ccRCC, which makes BIRC5 be an effective biomarker for predicting the prognosis of patients in ccRCC. BIRC5 may be a great potential biomarker for early diagnosis of ccRCC.

Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma

PROTEOMICS ◽  
2008 ◽  
Vol 8 (15) ◽  
pp. 3194-3203 ◽  
Author(s):  
Noboru Okamura ◽  
Taro Masuda ◽  
Akinobu Gotoh ◽  
Toshiro Shirakawa ◽  
Shuji Terao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Therapeutic Targets ◽  
Diagnostic Markers ◽  
Human Renal Cell Carcinoma ◽  
Quantitative Proteomic Analysis
Sign in / Sign up

Export Citation Format

Share Document